News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
XRP Price Was Shown In A Prophetic Vision. Here’s the Set Price
TimesTabloid·2026/04/23 16:06
Next Big Crypto Watchlist: BlockDAG, Cardano, Solana, and Bitcoin Cash Everyone Is Watching This April
BlockchainReporter·2026/04/23 15:57
Zambia’s Luanshya copper mine to restart in August after two-decade halt
Mining.com·2026/04/23 15:48
The ‘$10 XRP Price’ Pipe Dream Gets Killed Off by Big Banks. Here’s Why.
Tipranks·2026/04/23 15:48
Tether freezes 2 whale Tron wallets worth $344M in minutes as active addresses drop by 21%
Cryptopolitan·2026/04/23 15:45
US Banking Rule Reset Puts XRP, HBAR & XLM In The Spotlight
DailyCoin·2026/04/23 15:42
USD/TRY: Year-end target at 55.0 – Commerzbank
FXStreet·2026/04/23 15:42
AME: British Columbia government paralysis on DRIPA hurting mining future
Mining.com·2026/04/23 15:39
If You Thought XRP On Solana Was Big News, You Need to See This
TimesTabloid·2026/04/23 15:36
Could Ripple XRP Power Cross-Border Payments? Russia’s Early Tests Suggest Potential
Newsbtc·2026/04/23 15:33
Flash
11:40
Moderna, Inc. recently revealed that the company is actively planning its future product pipeline, and it is expected that as many as three new vaccine products may be launched between 2027 and 2028.These potential new products include a combined vaccine that protects against both influenza and COVID-19, an updated vaccine for seasonal influenza, and a new vaccine designed to prevent norovirus infection. This plan highlights Moderna’s ongoing expansion and in-depth application of its mRNA technology platform. The company is committed to extending its core mRNA research and development capabilities from the successful response to the COVID-19 pandemic to a broader range of respiratory and even gastrointestinal infectious diseases. If the combined influenza and COVID-19 vaccine is successfully launched, it could simplify public health immunization procedures and provide people with more convenient and comprehensive protection options. The development of a norovirus vaccine marks an important step for the company into a new field of disease prevention.Market analysts have pointed out that if this product pipeline plan progresses smoothly, it could open up new growth opportunities for Moderna in the coming years and strengthen its leading position in the global biotechnology and vaccine sectors. Investors are closely monitoring the progress of these research and development projects as well as their commercialization prospects.
11:40
SK Hynix Denies Rumors of 'Trillion Won Shareholder Return Plan': Never Discussed Specific ScaleBlockBeats News, June 16th - According to Jiemian News, on the evening of June 16th, regarding the market rumor of "SK Hynix's Plan for Trillion KRW Shareholder Return," it was revealed that the rumored scale of the huge return is not accurate.
SK Hynix stated that it is "exploring various options to enhance shareholder value, but the company has never discussed specific details such as the scale of shareholder return mentioned in the report."
11:40
Moderna, Inc. announced the appointment of Ester Banque as the company's Chief Commercial Officer, effective June 15, 2026.As Chief Business Officer, Banque will be fully responsible for the company's global business strategy, market access, and sales operations, leading the team to drive the commercialization of the company's product portfolio. This senior management change aims to strengthen Moderna's leadership in global commercial operations to respond to the ever-changing market environment and seize future growth opportunities.